Atreca is a clinical-stage biotech company inverting the traditional approach to cancer drug discovery. The company’s “Immune Repertoire Capture” (IRC) platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. This platform allows Atreca to identify novel targets in oncology and develop antibodies against those targets at a more rapid pace.
Atreca’s lead compound, ATRC-101, binds to a novel target and has demonstrated anti-tumor activity in the clinic. Interim data from this program have validated the platform’s ability to identify active therapeutic antibodies against novel targets in oncology. Additional interim data from Atreca’s phase 1b study evaluating ATRC-101 is expected in late 2022.
Atreca’s lead compound, ATRC-101, binds to a novel target and has demonstrated anti-tumor activity in the clinic. Interim data from this program have validated the platform’s ability to identify active therapeutic antibodies against novel targets in oncology. Additional interim data from Atreca’s phase 1b study evaluating ATRC-101 is expected in late 2022.
Ticker:
BCEL
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2010
Main Therapeutic Focus:
Oncology
Lead Product in Development:
ATRC-101
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
.jpg)
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
